Crestline Management’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-185,840
| Closed | -$3.24M | – | 601 |
|
|
2024
Q4 | $3.24M | Buy |
185,840
+65,115
| +54% | +$1.13M | 0.11% | 208 |
|
|
2024
Q3 | $1.69M | Buy |
120,725
+17,372
| +17% | +$243K | 0.09% | 204 |
|
|
2024
Q2 | $850K | Buy |
103,353
+19,454
| +23% | +$160K | 0.07% | 153 |
|
|
2024
Q1 | $647K | Buy |
83,899
+2,476
| +3% | +$19.1K | 0.06% | 152 |
|
|
2023
Q4 | $732K | Buy |
81,423
+20,002
| +33% | +$180K | 0.06% | 148 |
|
|
2023
Q3 | $549K | Hold |
61,421
| – | – | 0.06% | 135 |
|
|
2023
Q2 | $943K | Buy |
61,421
+1,421
| +2% | +$21.8K | 0.1% | 142 |
|
|
2023
Q1 | $1.35M | Buy |
+60,000
| New | +$1.35M | 0.16% | 112 |
|
|
2022
Q3 | – | Sell |
-44,119
| Closed | -$1.07M | – | 265 |
|
|
2022
Q2 | $1.07M | Buy |
44,119
+5,474
| +14% | +$133K | 0.14% | 118 |
|
|
2022
Q1 | $996K | Buy |
+38,645
| New | +$996K | 0.12% | 138 |
|